Ken Kato, MD, PhD, a medical oncologist at the National Cancer Center of Tokyo, and investigator in the pivotal CheckMate 648 study, underscores relevant safety data updates from the trial and important symptom management considerations with the FDA-approved combinations.
Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.
Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.
Elderly patients receiving novel-androgen hormonal therapies, such as abiraterone and enzalutamide, listed forgetfulness as their No. 1 reason for not taking prescribed pills.
Relatlimab, a human LAG-3 blocking antibody, plus nivolumab, elicited superior progression-free survival in patients with advanced melanoma compared to nivolumab alone.
Investigators reported an objective response rate of 43% and a disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer who received the KRAS G12C inhibitor adagrasib.
Frontline treatment with lenvatinib plus pembrolizumab decreased risk of disease progression or death by 50% compared with sunitinib in advanced renal cell carcinoma.
At data cutoff, all treated patients in a phase 2 trial experienced a clinical complete response with single-agent dostarlimab-gxly.
Patients with multiple myeloma who received initial combination therapy with lenalidomide, bortezomib, and dexamethasone, plus autologous stem cell transplant, followed by lenalidomide maintenance, experienced improved progression-free survival.
Patients with early-stage breast cancer who have low vitamin D counts may be at risk of developing chemotherapy-induced peripheral neuropathy.
Reducing ribociclib dosing by 200 mg or 400 mg did not affect overall survival in patients with hormone receptor–positive, HER2-negative, advanced breast cancer.
Findings from DESTINY-Breast04 (NCT03734029) support the use of trastuzumab deruxtecan in patients with hormone receptor–positive, HER2-low metastatic breast cancer.
Panitumumab with mFOLFOX demonstrated a clinical benefit for patients with left-sided RAS wild-type metastatic colorectal cancer in the PARADIGM trial (NCT02394795).
Updated safety findings from DESTINY-Breast03 showed that treatment with trastuzumab deruxtecan was safe and tolerable for patients with HER2-positive metastatic breast cancer.
Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Patients with KRAS wild-type pancreatic cancer elicited a significant survival benefit with the addition of nimotuzumab to gemcitabine vs placebo plus gemcitabine in a phase 3 trial.
Avasopasem was associated with a significant reduction in severe oral mucositis in patients with locally nonmetastatic head and neck cancer undergoing chemoradiotherapy.
Although 83% of Black patients with metastatic breast cancer expressed interest in clinical trials, only 40% reported having a conversation about enrollment with their health care provider, highlighting one of many potential barriers to achieving clinical trial diversity.
Kellie Zeichner, RN, BSN, OCN, discusses the production of biosimilars, their approval and naming processes, and why immunogenicity is important when discussing these agents.
Updates to the NCCN guidelines for patients with resectable early-stage NSCLC now include neoadjuvant and adjuvant regimens with chemotherapy, immunotherapy, and targeted therapies, which promise to change biomarker testing practice.
Lisa Vigil Schattinger, MSN, RN, discusses her experience with medical aid in dying, and what oncology nurses need to understand when supporting patients at the end of their lives.
Standard chemotherapy plus sorafenib achieved clinical benefit in pediatric patients with FLT3-ITD–positive acute myeloid leukemia.
In this episode of The Vitals, Donna Herrera Bell, MSN, APRN, FNP-C, highlights how nurses can eliminate barriers to fertility discussions among adolescent and young adult patients with cancer.
The rise of social media platforms has helped foster a community for adolescent and young adult patients with cancer.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from May 2022.
Patient-reported outcome collections continue to yield more effective and personalized treatments for patients with cancer.
Nurse investigators characterized the onset and management of edema and effusion with loncastuximab tesirine in the pivotal LOTIS-2 trial.
Investigators reported that mitomycin gel was not associated with decrements in urinary symptoms, bloating and flatulence, or malaise, and that sexual function only mildly worsened.
Tisagenlecleucel received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
Nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab received FDA approval as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status
